Stryker Corporation (SYK) Fair Value 2026

SYK · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.0 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-08-28, Stryker Corporation (SYK) trades at $330.69, versus a $176.97 median fair value across its 11 active models — 46.5% below the current price. QOC: 9.0/10. Value Trap Risk: 12/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $274.13.

Key Facts

Ticker
SYK
Price
$330.69
Quality Score
9.0/10
Value Trap Risk
12/100
Models Active
11/13
Last Updated
Strength: First Chicago suggests +0.2% upside with 66% confidence
Risk: Majority of models suggest overvaluation

Is Stryker Corporation (SYK) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Stryker Corporation (SYK) appears overvalued as of : the median of 11 independent fair value estimates is $176.97, 46.5% below the current price of $330.69. Estimates range from $56.68 to $510.00. SYK scores 9.0/10 on fundamental quality and 12/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. SYK’s -46.5% gap is wider than that market norm, and the Medical Devices sector median is -43.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Stryker Corporation Stock in 2026? →

What Fair Value Does Each Model Give SYK?

11 Intrinsic Value Models vs. Current Price ($330.69)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $274.13 -17.1%
Intrinsic · High Conviction
 $71.89 -78.3%
Ensemble · Low Conviction
 $176.97 -46.5%
Scenario · High Conviction
 $331.51 +0.2%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is SYK's Fair Value Range?

Spread across 11 independent models · $56.68 to $510.00

CirclFi's 11 active models place Stryker Corporation (SYK) between $56.68 and $510.00 per share, a spread of 256% of the median. The median of that range — $176.97 — is the fair value CirclFi publishes for SYK, against a current price of $330.69.

Low · Markov DDMHigh · Regime Cross
$56.68median $176.97$510.00
Where the range comes from
Most bearish modelMarkov DDM$56.68
Most bullish modelRegime Cross-Sectional$510.00
Model agreement1 bullish · 9 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for SYK. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on SYK, not a CirclFi price target. How each model works →

What Is Stryker Corporation (SYK) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Stryker Corporation's intrinsic value is estimated at $176.97, suggesting the stock is overvalued at its current price of $330.69. With 9 out of 11 models flagging downside (-46.5% vs price), the market may be pricing in unsustainable growth. Notably, Regime Cross sees the most upside at +54.2% (fair value: $510.00), while Markov DDM is the most conservative at -82.9% ($56.68). The spread between these extremes — +137.1% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, Bayesian DCF, EPV, EROIC lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About SYK?

11 of 13 models are currently active for SYK. Of these, 2 models suggest upside while 9 models suggest overvaluation. Taken together, their median fair value for SYK is $176.97 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $274.13 on its own, implying -17.1% downside from the current price. See which stocks rank higher →

How Does SYK Rank in Medical Devices?

Among 159 Medical Devices stocks, SYK ranks #8 by Quality of Company score. CirclFi's QOC score of 9.0/10 evaluates 32 fundamental signals. A score of 9.0 places SYK in the top tier.

See all Most Undervalued Medical Devices Stocks →

As a healthcare company, Stryker Corporation operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating SYK should weigh these sector-specific dynamics alongside our model-derived fair values.

Is SYK a Value Trap?

CirclFi's Value Trap algorithm assigns SYK a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Stryker Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Stryker Corporation is rated at 9.0/10. This elite-tier score ranks among the highest-quality businesses in our coverage universe.

The gap between the most bullish and bearish model spans +137.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SYK valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SYK's 11 active models, average confidence is 58%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Stryker Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

ELMDElectromed, Inc.QOC 9.1INSPInspire Medical Systems, Inc.QOC 9.0TMDXTransMedics Group, Inc.QOC 9.2BSXBoston Scientific CorporationQOC 8.9UFPTUFP Technologies, Inc.QOC 9.2PENPenumbra, Inc.QOC 8.9LNSRLENSAR, Inc.QOC 7.1BBNXBeta Bionics, Inc.QOC 6.1HSCSHeartSciences Inc.QOC 4.9IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: ELMD · INSP · TMDX · BSX · UFPT · PEN · LNSR · BBNX · HSCS · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to SYK?

7 companies across all industries closest to SYK’s Quality of Company score of 9.0/10.

KAROKarooooo Ltd.QOC 9.0EXPEExpedia Group, Inc.QOC 9.0AGYSAgilysys, Inc.QOC 9.0ONCBeOne Medicines AGQOC 9.0LULUlululemon athletica inc.QOC 9.0FLNGFLEX LNG Ltd.QOC 9.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: KARO · EXPE · AGYS · ONC · LULU · FLNG · NVDA

Where Does SYK Sit in CirclFi's Medical Devices Rankings?

SYK is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Stryker Corporation’s Valuation?

What is Stryker Corporation's intrinsic value in 2026?

CirclFi puts Stryker Corporation (SYK)'s intrinsic value at $176.97 — the median of 11 independent model estimates as of 2026-08-28, ranging from $56.68 to $510.00. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $274.13 on its own. The Quality of Company score is 9.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SYK overvalued or undervalued right now?

At $330.69, 2 of 11 active models suggest SYK may be undervalued, while 9 indicate potential overvaluation. The median of all 11 fair value estimates is $176.97, 46.5% below the current price of $330.69 — a consensus view that SYK is overvalued. The assessment depends on which methodology best fits Stryker Corporation's business model in Medical Devices.

What does a Quality of Company score of 9.0 mean for SYK?

Stryker Corporation's QOC of 9.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on SYK?

CirclFi analyzes SYK with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on SYK?

Of the 11 models currently active on SYK, Regime Cross-Sectional is the most bullish at $510.00 per share, and Markov DDM is the most bearish at $56.68. CirclFi's published fair value for SYK is the median of that range, $176.97, not either extreme. The gap between the two ends equals 256% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is SYK a value trap in 2026?

Stryker Corporation's Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Stryker Corporation (SYK) has a median fair value of $176.97 — 46.5% below the current price of $330.69 — as of 2026-08-28.” Source: circlfi.com/stock/SYK/ · Methodology
Primary sources for this SYK valuation
  • Financial statements: Stryker Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0000310764) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SYK as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on SYK.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for SYK Unlock All 11 — $39/mo